LEGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Legend Biotech Corp (LEGN) is not a strong buy for a beginner, long-term investor at this time. While the company has shown impressive revenue growth, its financial performance is weighed down by significant net income losses and declining EPS. Additionally, the stock is currently overbought based on RSI, and there are no strong proprietary trading signals to support immediate action. Analysts have mixed views, with some downgrades and reduced price targets, reflecting concerns about competition and slower-than-expected uptake of its key product, Carvykti. For a long-term investor, it may be better to wait for more clarity on the company's competitive positioning and financial improvement.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI at 80.483 suggests the stock is overbought. The stock is trading near its resistance level (R1: 21.146), with converging moving averages hinting at potential consolidation. Key support levels are at 19.488 and 17.83.
Analysts highlight strong execution in Carvykti's opportunity, with favorable risk/reward at current levels. Deutsche Bank estimates peak gross Carvykti sales at $7B, with Legend's share at $3.5B.
Net income dropped significantly (-217.24% YoY) in Q4 2025, with EPS also declining (-214.29% YoY). Concerns about competition and toxicity issues for Carvykti are impacting demand. Analysts have downgraded the stock and lowered price targets. The RSI indicates the stock is overbought, suggesting limited immediate upside.
In Q4 2025, revenue increased by 64.26% YoY to $306.38M. However, net income dropped significantly to -$30.82M (-217.24% YoY), and EPS fell to -0.08 (-214.29% YoY). Gross margin slightly declined to 59.7% (-1.11% YoY).
Analyst sentiment is mixed. RBC Capital and Morgan Stanley maintain positive ratings but have lowered price targets. Deutsche Bank sees favorable risk/reward but acknowledges competition concerns. Other firms, such as Rothschild & Co Redburn and TD Cowen, have downgraded the stock, citing competition and slower-than-expected uptake of Carvykti.
